Clinical trials: Objective Response Rate, open to volunteers
Bone Sarcoma, Osteosarcoma
Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients
This is a multicenter phase II study concerning patients with high-grade bone sarcoma (HGBS) without complete remission after standard treatment at diagnosis or at relapse.
- Trial name
- REGOMAIN (NCT04698785)
- Testing
- Treatment by regorafenib and best supportive care
- Where
- 16 sites in France
- Volunteers
- 36 people
- Sponsor
- Centre Leon Berard
Pathological Complete Remission, Objective Response Rate
Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma
This study is a prospective, single-arm, phase II exploratory clinical trial. The primary endpoint of this study is to evaluate the pathological complete response (pCR) rate after surgery and to assess the safety of neoadjuvant…
- Conditions
- Pathological Complete Remission, Objective Response Rate, Immune-related Adverse Events, Quality of Life
- Trial name
- NCT07430579
- Testing
- adebrelimab combined with chemotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- The Second Hospital of Shandong University
Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancers
Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer
This is a prospective, single-center, single-arm exploratory clinical study designed to evaluate the efficacy and safety of liposomal irinotecan combined with enlonstobart in patients with platinum-resistant recurrent ovarian…
- Conditions
- Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancers, Epithelial Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT07591831
- Testing
- Liposomal Irinotecan
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Adenoid Cystic Carcinoma, Sinonasal Carcinoma
Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study
This study is for patients with locally advanced sinonasal adenoid cystic carcinoma (SNACC), a rare and challenging cancer that tends to invade nerves and the skull base.
- Conditions
- Adenoid Cystic Carcinoma, Sinonasal Carcinoma, Epirubicin
- Trial name
- EIC-SNACC (NCT07320508)
- Testing
- Epirubicin (E)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Diffuse Large B-cell Lymphoma
R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse
This is a double-center, single-arm, phase 2 study to evaluate the efficacy and safety of R-CDOP regimen combined with intrathecal methotrexate in chemo-naive diffuse large B-cell lymphoma patients with high-risk of CNS relapse.
- Trial name
- NCT05257018
- Testing
- R-CDOP+intrathecal MTX
- Where
- 2 sites in China
- Volunteers
- 83 people
- Sponsor
- Fudan University
Breast Cancer, HER2-positive Breast Cancer
Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer
This study is intended to carry out a single arm, prospective, open clinical study, and use Darsilide combined with endocrine therapy, Trastuzumab and Patuzumab to treat early or locally advanced breast cancer of TPBC before…
- Trial name
- NCT06276868
- Testing
- Dalcilib+letrozole+HP treatment group
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Henan Cancer Hospital
BRAF V600 Colorectal Cancer
Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer
The goal of this clinical trial is to learn if Iparomlimab and Tuvonralimab combined with bevacizumab and FOLFIRI (IB-FOLFIRI) is safe and effective in treating adults with BRAF V600E-mutant metastatic colorectal cancer (mCRC).
- Trial name
- NCT07150247
- Testing
- Iparomlimab and Tuvonralimab, Bevacizumab, 5-Fluorouracil
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sun Yat-sen University
Malignant Solid Tumors With Lymph Node Metastasis
Real-World Study on Efficacy and Influencing Factors of Immunotherapy for Pan-Cancer Lymph Node Metastases.
Lymph node metastasis is a key stage of malignant tumor progression and a core factor affecting the efficacy of immunotherapy. The therapeutic response of lymph node metastases to immune checkpoint inhibitors (ICIs) varies…
- Trial name
- NCT07540377
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Head and Neck Cancer Squamous Cell Carcinoma, Skull Base--Cancer
Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base
This prospective, single-arm, Phase II clinical trial aims to evaluate the efficacy and safety of tislelizumab combined with chemotherapy as neoadjuvant therapy and postoperative adjuvant immunotherapy in patients with skull…
- Conditions
- Head and Neck Cancer Squamous Cell Carcinoma, Skull Base--Cancer, Neoadjuvant Chemoimmunotherapy, Objective Response Rate
- Trial name
- NCT07145931
- Testing
- Neoadjuvant chemoimmunotherapy, Tislelizumab Nab paclitaxel
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
Advanced Bladder Cancer
The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder Cancer
The goal of this clinical trial is to learn if the timing of treatments plays a role in how effective the standard-of-care drugs enfortumab vedotin and pembrolizumab (EV/P) works to treat adults with advanced bladder cancer.
- Trial name
- Chrono-EVP (NCT07346053)
- Testing
- enfortumab vedotin and pembrolizumab (EV/P)
- Where
- 5 sites in Canada
- Volunteers
- 224 people
- Sponsor
- Guliz Ozgun
Peripheral T-cell Lymphoma
Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma
This is a single-center, single-arm, phase 2 study to evaluate the efficacy and safety of Anti-PD-1 antibody(Sintilimab) plus HDAC inhibitor(Chidamide) in patients with relapsed/refractory peripheral T-cell lymphoma (r/r PTCL).
- Trial name
- Sincerely20 (NCT04512534)
- Testing
- PD-1 antibody+ HDAC inhibitor
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Fudan University
Soft Tissue Sarcoma (STS)
Spatially Fractionated Radiotherapy Versus Conventional Radiotherapy in the Treatment of Soft Tissue Sarcoma
This study is a multicenter, prospective, randomized controlled phase II clinical trial designed to evaluate the efficacy and safety of Spatially Fractionated Radiation Therapy (SFRT) compared to Conventional Radiation Therapy…
- Trial name
- NCT06980259
- Testing
- Spatially Fractionated Radiotherapy, Conventional Radiotherapy
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Shandong Cancer Hospital and Institute
Hepatocellular Carcinoma
Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma
This study will look at whether adding daily oral zinc supplements to targeted therapy plus immunotherapy may help people with unresectable or advanced hepatocellular carcinoma, a common type of liver cancer.
- Trial name
- ZINC-1LT/IOHCC (NCT07793695)
- Testing
- Oral elemental zinc supplementation, 20 mg/day, Oral elemental zinc supplementation, 30 mg/day, Standard-of-care targeted therapy plus immunotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Anhui Provincial Hospital
Gastric (Stomach) Cancer
Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
The purpose of this study is to evaluate the objective response rate (ORR) of Pembrolizumab combined with Lenvatinib and SOX compared with SOX alone in the treatment of patients with HER2-negative advanced gastric or…
- Trial name
- FUGES032 (NCT07356466)
- Testing
- Pucotenlimab Combined with Lenvatinib, Oxaliplatin plus S-1 regimen
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fujian Medical University
Colorectal Liver Metastases
Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases
The goal of this clinical trial is to learn if ivonescimab plus chemotherapy works to treat colorectal cancer liver metastases that cannot be completely removed. It will also learn about the safety of ivonescimab.
- Trial name
- NCT06848842
- Testing
- Ivonescimab plus chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Head and Neck Squamous Cell Carcinoma
Becotatug Vedotin Plus PD-1 Inhibitor for Head and Neck Squamous Cell Carcinoma
This is a prospective, open-label, non-randomized, two-cohort, single-arm Phase 2 study in adults with unresectable or recurrent/metastatic head and neck squamous cell carcinoma, excluding nasopharyngeal carcinoma.
- Trial name
- NCT07683507
- Testing
- Becotatug Vedotin Combined with PD-1 Inhibitor
- Volunteers
- 60 people
- Sponsor
- Feng Liu
Metastatic Castration-resistant Prostate Cancer
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor…
- Trial name
- NCT06520345
- Testing
- 177Lu-TLX591, Enzalutamide, Abiraterone
- Where
- 33 sites in United States, Australia and 4 more
- Volunteers
- 520 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited